GH Research (NASDAQ:GHRS) Now Covered by Analysts at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald assumed coverage on shares of GH Research (NASDAQ:GHRS) in a report issued on Thursday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $14.00 price target on the stock.

Several other analysts have also recently commented on GHRS. Canaccord Genuity Group reduced their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of GH Research in a report on Monday, January 27th.

GH Research Price Performance

Shares of NASDAQ:GHRS opened at $14.00 on Thursday. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The firm’s 50-day simple moving average is $9.37 and its 200-day simple moving average is $9.07. The company has a market cap of $728.42 million, a price-to-earnings ratio of -17.72 and a beta of 0.93.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. grew its stake in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).